scholarly journals The efficacy of the symptomatic therapy of the non-atopic bronchial asthma attack in schoolchildren

2014 ◽  
Vol 18 (1 (69)) ◽  
Author(s):  
S. I. Sazhyn
Keyword(s):  
Bronchial Asthma ◽  
Symptomatic Treatment ◽  
Atopic Asthma ◽  
Bronchial Obstruction ◽  
Symptomatic Therapy ◽  
Asthma Phenotype ◽  
Atopic Bronchial Asthma ◽  
Asthma Attack ◽  
Hospitalization Period ◽  
Comparison Groups

The effectiveness of symptomatic treatment of bronchial asthma in children has been studied. It has been found that patients with non-atopic asthma phenotype were characterized by more severe bronchial obstruction during exacerbations compared with atopic patients. Children afflicted with nonatopic phenotype of the disease were characterized by more pronounced signs of airway obstruction during the whole hospitalization period despite the identical standard regimens in the comparison groups.

scholarly journals Effects of the Airway Obstruction on the Skin Microcirculation in Patients with Bronchial Asthma

2016 ◽  
Vol 71 (3) ◽  
Author(s):  
Irina V. Tikhonova ◽  
N. I. Kosyakova ◽  
A. V. Tankanag ◽  
N. K. Chemeris
Keyword(s):  
Blood Flow ◽  
Airway Obstruction ◽  
Bronchial Asthma ◽  
Skin Blood Flow ◽  
Peripheral Blood ◽  
Atopic Asthma ◽  
Control Group ◽  
Bronchial Obstruction ◽  
Peripheral Blood Flow ◽  
Flow Parameters

Background: Pulmonary hemodynamic disorders depend on the inflammatory phases and severity of the obstructive syndrome. However, the effect of asthma bronchial obstruction on the state of peripheral hemodynamics remains insufficiently known. Aims: To study the effects of airway obstruction on skin blood flow parameters and its regulatory systems in patients with persistent atopic bronchial asthma in the remission state.Materials and methods: A comparative study of the skin peripheral blood flow in patients with bronchial asthma with severe airway obstruction (1st group) and without obstruction (2nd group) was conducted. 20 patients with confirmed diagnosis of atopic asthma of 50–74 years old participated in the study. All patients received basic therapy in a constant dosing of high doses of inhaled glucocorticosteroids/long-acting beta-2-agonists. The control group included 20 healthy volunteers without evidence of bronchial obstruction. The study lasted for 3 months. The forced expiratory volume in 1 s (FEV1) was used to evaluate the bronchial obstruction by spirometry technique. Skin blood perfusion changes were recorded by laser Doppler flowmetry at rest and in response to short-term local ischemia. Registered peripheral blood flow signals were examined using the amplitude temporal filtering in five frequency intervals to identify the functional features of the peripheral blood flow regulation systems. Results: Consistent two-fold decrease of the oscillation amplitudes was found in the neurogenic interval at rest (p=0.031), as well as in the myogenic (p=0.043; p=0.031) and endothelial intervals (p=0.037; p≤0.001) both at rest and during the postocclusive reactive hyperemia respectively in the 1st group of patients with bronchial obstruction (FEV1 80%) compared with the control group. No significant changes were revealed for skin blood flow parameters in the 2nd patient group (without obstruction, FEV1 80%) in comparison to control subjects.Conclusions: The presence of bronchial obstruction has a significant impact on the changes of the amplitudes of skin blood flow oscillations in patients with bronchial asthma in the myogenic, neurogenic and endothelial intervals.

scholarly journals THE EFFECT OF MAGNETO-LASER THERAPY ON THE PHENOTYPE OF BASOPHILS IN CHILDREN WITH ATOPIC ASTHMA

2019 ◽  
Vol 29 (2) ◽  
pp. 35-38
Author(s):  
Elena Asiryn ◽  
Pavel Novikov ◽  
Volha Matsiushchanka ◽  
Nadiezhda Titova ◽  
Lukas Vaidelys ◽  
...  
Keyword(s):  
Laser Therapy ◽  
Bronchial Asthma ◽  
Inhaled Corticosteroids ◽  
Atopic Asthma ◽  
Relative Level ◽  
Atopic Bronchial Asthma ◽  
Significant Difference ◽  
Group A ◽  
The Absolute ◽  
Group B

In recent years there has been growing evidence to suggest a major role of basophils alongside eosinophils and mast cells in allergic inflammation. The aim of this study was to analyze the dynamics of the basophil phenotypes after the use of magneto-la-ser therapy in children with atopic bronchial asthma. Materials and methods. A total of 66 children with mild persistent atopic bronchial asthma (aged 6 to 18 years old) were examined. Group A included 34 children who received magneto-laser therapy together with basic asthma treatment (low dose of inhaled corticosteroids). Group B included 32 children who received only basic asthma therapy. The level of CD203с + , CD203с + CD63 + , CD203с + IgE + basophils was determined in peripheral blood in the beginning of the study, after 2 weeks and after 3 months. Results. A statistically significant decrease in the absolute levels of CD203с+CD63+ and CD203с + IgE + basophils and in the relative level of CD203с + IgE + among all CD203с + basophils was determined in group A after magneto-laser therapy. The comparison of group A and group B indices revealed a significant difference between the relative level of CD203с + IgE + basophils after 12-15 days from the beginning of the study. This indicator was significantly lower in group A than in group B (p<0.05). The absolute level of CD203с + IgE + basophils was significantly lower in group A in comparison with group B after 82-90 days (p<0.05). Conclusions. Magneto-laser therapy can change the phenotype of basophils in children with atopic bronchial asthma, causing suppression of proallergic pa-rameters. Considering these results there is reason to believe, that it is possible to use this method as an additional immunocorrective treatment in patients with basophilic phenotype of atopic asthma.

РАСПРОСТРАНЕННОСТЬ ФЕНОТИПОВ ТЯЖЕЛОЙ БРОНХИАЛЬНОЙ АСТМЫ НА СРЕДНЕМ УРАЛЕ

2019 ◽  
Author(s):  
E.K. Beltyukov ◽  
V.V. Naumova ◽  
V.Ch. Abdullaev ◽  
Y.A. Styazhkina ◽  
S.S. Vedenskaya
Keyword(s):  
Targeted Therapy ◽  
Severe Asthma ◽  
Bronchial Asthma ◽  
Cost Effective ◽  
Atopic Asthma ◽  
Practical Significance ◽  
Asthma Prevalence ◽  
Uncontrolled Asthma ◽  
Asthma Phenotype ◽  
Number Of Patients

Обоснование. Тяжелая БА является гетерогенным и экономически затратным заболеванием, что требует персонифицированного подхода к лечению с включением таргетной терапии, предполагающей фенотипирование астмы. Цель. Определение динамики распространенности бронхиальной астмы (БА) на Среднем Урале, в том числе тяжелой БА, и проведение фенотипирования пациентов с тяжелой БА для определения потребности в таргетной терапии. Материалы и методы. Популяционные исследования распространенности БА проводились на Среднем Урале с 2000 по 2012 г. с использованием стандартного вопросника ECRHS создавались регистры больных БА. В 2018 г. в г. Екатеринбурге проведен анализ амбулаторных карт пациентов с БА (n216). Фенотипирование БА проводилось врачом аллергологом-иммунологом. Результаты. На Среднем Урале за 17 лет число больных БА увеличилось в 2,7 раза. В популяции превалируют больные с легким течением астмы в 70,8-81 случаев преобладает атопический фенотип вне зависимости от категории населения. В структуре зарегистрированных по обращаемости больных астмой тяжелая неконтролируемая БА составляет 10,2. Каждый второй пациент с тяжелой неконтролируемой астмой имеет атопический фенотип, что составляет 5 от числа всех случаев БА каждый четвертый больной из данной группы имеет эозинофильной фенотип, что составляет 2,3 от числа всех случаев (n216). Заключение. Фенотипирование БА имеет важное прикладное значение для планирования эффективной таргетной терапии в популяции больных тяжелой неконтролируемой астмой.Topicality. Severe asthma is a heterogeneous and cost-effective disease that requires a personalized treatment approach with inclusion of targeted therapy involving the phenotyping of asthma. Objective. Determine the dynamics of asthma prevalence in the Middle Ural, including severe asthma, and phenotype patients with severe asthma for the selection of targeted therapy. Materials and methods. Population studies of bronchial asthma prevalence were conducted in the Middle Ural from 2000 to 2012 using the standard ECRHS questionnaire. Also registers of patients with asthma were created. An analysis of outpatient records of patients with asthma was conducted in Ekaterinburg in 2018. The phenotyping of bronchial asthma was carried out by an allergist-immunologist. Results. The number of patients with bronchial asthma increased by 2.7 times over 17 years in the Middle Ural. Patients with mild asthma prevail in the population. The atopic asthma phenotype predominates in 70.8-81 of cases regardless of the population category. Severe uncontrolled bronchial asthma occurs in 10.2 of cases among all patients seeking medical care. Every second patient with severe uncontrolled asthma has an atopic phenotype, which is 5 of the total number of analyzed patients with bronchial asthma. Every fourth patient with severe uncontrolled bronchial asthma has an eosinophilic phenotype, which is 2.3 of all analyzed patients with bronchial asthma (n216). Conclusion. Phenotyping of asthma has important practical significance for planning effective targeted therapy in a population of patients with severe uncontrolled asthma.

scholarly journals ECONOMIC ASPECTS OF APPLICATION OF THE RUSSIAN BIOSIMILAR OMALIZUMAB IN PATIENTS WITH ATOPIC BRONCHIAL ASTHMA OF MODERATE TO SEVERE CLINICAL COURSES

2021 ◽  
Vol 9 (3) ◽  
pp. 235-248
Author(s):  
V. S. Krysanova ◽  
E. D. Ermolaeva ◽  
T. N. Ermolaeva ◽  
M. V. Davydovskaya ◽  
K. A. Kokushkin
Keyword(s):  
Monoclonal Antibodies ◽  
Medical Care ◽  
Bronchial Asthma ◽  
Impact Analysis ◽  
Budget Impact ◽  
Budget Impact Analysis ◽  
Adult Patients ◽  
Atopic Asthma ◽  
Atopic Bronchial Asthma ◽  
Number Of Patients

A certain success in the treatment of bronchial asthma is associated with the introduction of monoclonal antibodies into the treatment process. They made it possible to improve the control of the disease. A number of original genetically engineered biological drugs, such as benralizumab, reslizumab, dupilumab, mepolizumab and omalizumab, are currently registered in Russia. In 2020, this list was supplemented by the first Russian biosimilar drug omalizumab – Genolar® (JSC Generium, Russia). High rates of the development of modern medicine are closely related to the use of biosimilars. The prescription of biosimilars today often makes it possible to provide a larger number of patients with modern drugs at lower costs.The aim of the study was a comprehensive pharmacoeconomic assessment of the application of the domestic biosimilar drug omalizumab in the treatment of patients suffering from moderate and severe atopic bronchial asthma.Materials and methods. At the first stage, an information search in the available databases (Cochrane Library, MedLine, Embase, eLIBRARY) was carried out. According to the results obtained, a meta-analysis (Agache I. et al.) was found out; within its framework, the efficacy and safety of the use of several monoclonal antibodies was assessed. Dupilumab was chosen as the reference drug. Pharmacoeconomic analyses were carried out using a “Cost-Minimization Analysis” (CMA) and a “Budget Impact Analysis” (BIA). Taking into account various options of bronchial asthma, the developed algorithm for providing medical care to adult patients with atopic asthma made it possible to assess the costs, including direct medical and indirect costs.Results. The cost analysis demonstrated the advantage of using the Russian biosimilar omalizumab in patients with atopic asthma compared to dupilumab due to financial savings of up to 40%. The Budget Impact Analysis showed that the use of the domestic biosimilar omalizumab, even taking into account the annual increase in the number of patients (8%), will save up to 109,641,409.64 rubles (or 3%) compared to the current practice.Conclusion. The use of the domestic biosimilar omalizumab in patients with moderate to severe atopic bronchial asthma is a clinically effective and economically justified approach to organizing medical care for adult patients in Russia.

scholarly journals Serum apelin-12 in bronchial asthma

2014 ◽  
Vol 95 (5) ◽  
pp. 631-636
Author(s):  
V N Mineev ◽  
T M Lalaeva ◽  
A A Kuzmina
Keyword(s):  
Serum Level ◽  
Bronchial Asthma ◽  
Peripheral Blood ◽  
Allergic Sensitization ◽  
Serum Levels ◽  
Atopic Asthma ◽  
Bronchial Obstruction ◽  
Blood Eosinophil ◽  
Inverse Association ◽  
Peripheral Blood Eosinophil

Aim. To evaluate the serum level of apelin-12 in patients with bronchial asthma. Methods. 11 healthy controls and 29 patients with bronchial asthma were examined (among them 19 with atopic asthma and 10 with non-atopic asthma). Serum apelin-12 levels were measured by enzyme immunoassay (ELISA, MyBioSource, USA). SPSS (Statistical Package for the Social Science, V. 13) for Windows was used for statistical analysis. Results. The phenomenon of low apelin-12 serum levels was revealed in patients with bronchial asthma. The most significant decrease of apelin-12 levels was noticed in atopic bronchial asthma. The apelin-12 levels were significantly correlated with a number of indices of bronchial obstruction. Apelin-12 levels correlated with a number of indicators characterizing the grade of bronchial obstruction. Moreover, low apelin-12 levels were suggesting bronchial obstruction. Besides, significant reverse correlation of apelin-12 levels and allergic sensitization was revealed. In addition, statistically significant relation between apelin-12 serum level and peripheral blood eosinophil and lymphocyte counts was revealed. There was an inverse association between apelin-12 serum level and peripheral blood neutrophil count. Conclusion. Literature analysis and our own results allow us to suppose the possible protective role of apelin-12 in bronchial asthma flare. Further studies of apelin-12 and of other isoforms of adipokines are needed for better understanding of the disease.

scholarly journals Initial vegetative tone in mild atopic asthma in children

2021 ◽  
Vol 12 (2) ◽  
pp. 13-18
Author(s):  
Vladimir N. Buryak ◽  
Tatyana I. Antonova ◽  
Maria V. Dudko ◽  
Inna V. Malysheva ◽  
Kirill K. Shepelenko
Keyword(s):  
Nervous System ◽  
Autonomic Nervous System ◽  
Bronchial Asthma ◽  
The Body ◽  
Atopic Asthma ◽  
World Health ◽  
Control Group ◽  
Healthy Children ◽  
Autonomic Nervous ◽  
Atopic Bronchial Asthma

Background. In most industrialized countries, allergic diseases affect up to 20% of the population. This pathology belongs to the most common in children: according to the World Health Organization, more than 15% of the world's child population suffers from it. In recent years, there has been a significant increase in the frequency and more severe course of these diseases, in connection with which they are considered in modern society as a major medical and social problem. Thus, the prevalence of bronchial asthma, according to domestic and foreign authors, ranges from 0.2 to 8.1%. Purpose. In order to clarify the role of the autonomic nervous system in the genesis of the mild course of atopic bronchial asthma in childhood, the features of the interaction of the sympathetic and parasympathetic divisions of the autonomic nervous system in the examined children were clarified. Materials and methods. 126 children aged 10 to 14 years were examined. Atopic bronchial asthma was diagnosed in 91 children. At the same time, 61 of them were diagnosed with an intermittent course, 30 a mild persistent course of the disease. The control group consisted of 35 healthy children also aged 10 to 14 years. Complaints, anamnesis data were studied in all children, an objective and generally accepted laboratory and instrumental examination was carried out. All examined children underwent daily monitoring of the electrocardiogram, according to the results of which, based on the analysis of time and frequency indicators of heart rate variability, a variant of the initial autonomic tone was established. Results. In children with atopic bronchial asthma, both with intermittent and mild persistent course, an absolute or relative dominance of sympathetic influences was revealed against the background of varying degrees of decrease in parasympathetic activity, which was interpreted as a compensatory reaction of the body in response to chronic allergic inflammation.

scholarly journals Comorbidity of atopic bronchial asthma and food allergy in adults

2021 ◽  
Author(s):  
Y. Zhorina ◽  
G. Ignatov ◽  
O. Abramovskikh ◽  
I. Zherebcova
Keyword(s):  
Food Allergy ◽  
Bronchial Asthma ◽  
Clinical Manifestations ◽  
Significant Risk ◽  
Atopic Asthma ◽  
Food Allergies ◽  
Atopic Bronchial Asthma ◽  
Increased Risk ◽  
Wide Range ◽  
Emergency Drugs

Adult patients with atopic bronchial asthma are susceptible to food allergy, in more than one third of cases, while asthma is a risk factor for severe life-threatening factors. The aim of the study was to determine the prevalence and relationship of food allergies with atopic bronchial asthma in adults living in Chelyabinsk. Materials and methods. An analysis of 313 outpatient case histories of patients with atopic bronchial asthma over the age of 18 was performed. Results. The presence of food allergy was a factor in the earlier onset of atopic bronchial asthma, which is consistent with the concept of comorbidity of these diseases. Patients with seasonal allergic rhinitis and pollen sensitization have an increased risk of developing food allergies (OR – 2.075 [1.27- 3.39]), p=0,004. The overall incidence of oral allergic syndrome among all patients with atopic asthma and plant sensitization was 33% [28; 37]. Plant products (fruits, honey, nuts) were the cause of food allergic reactions in 87% [80; 92] of adult cases. The main clinical manifestations were: oral allergic syndrome, urticaria, angioedema, shortness of breath. Sensitization to pollen of trees, grasses and weeds approximately equally increases the risk of developing an oral allergic syndrome, upon sensitization to tree pollen (OR – 3.08 [2.32-4.25]), to grass pollen (OR – 3.5 [2.23-5.61]), to weed pollen (OR – 2.86 [2.02-4.03]). The combination of several types of pollen sensitization increases by 4 times the risk of developing oral allergic syndrome to a wide range of foods. Conclusion. Data on the causes and clinical manifestations of food allergies in combination with bronchial asthma have been obtained. The notion of a significant risk of developing dangerous clinical manifestations of food allergy in patients with atopic bronchial asthma will make it possible to reasonably prescribe emergency drugs for independent use.

РАСПРОСТРАНЕННОСТЬ ФЕНОТИПОВ ТЯЖЕЛОЙ БРОНХИАЛЬНОЙ АСТМЫ НА СРЕДНЕМ УРАЛЕ

2019 ◽  
pp. 67-74
Author(s):  
E.K. Beltyukov ◽  
V.V. Naumova ◽  
V.Ch. Abdullaev ◽  
Y.A. Styazhkina ◽  
S.S. Vedenskaya
Keyword(s):  
Targeted Therapy ◽  
Severe Asthma ◽  
Bronchial Asthma ◽  
Atopic Asthma ◽  
Practical Significance ◽  
Asthma Prevalence ◽  
Uncontrolled Asthma ◽  
Asthma Phenotype ◽  
Number Of Patients ◽  
Selection Of

Обоснование. Тяжелая БА является гетерогенным и экономически затратным заболеванием, что требует персонифицированного подхода к лечению с включением таргетной терапии, предполагающей фенотипирование астмы. Цель. Определение динамики распространенности бронхиальной астмы (БА) на Среднем Урале, в том числе тяжелой БА, и проведение фенотипирования пациентов с тяжелой БА для определения потребности в таргетной терапии. Материалы и методы. Популяционные исследования распространенности БА проводились на Среднем Урале с 2000 по 2012 г. с использованием стандартного вопросника ECRHS создавались регистры больных БА. В 2018 г. в г. Екатеринбурге проведен анализ амбулаторных карт пациентов с БА (n216). Фенотипирование БА проводилось врачом аллергологомиммунологом. Результаты. На Среднем Урале за 17 лет число больных БА увеличилось в 2,7 раза. В популяции превалируют больные с легким течением астмы в 70,881 случаев преобладает атопический фенотип вне зависимости от категории населения. В структуре зарегистрированных по обращаемости больных астмой тяжелая неконтролируемая БА составляет 10,2. Каждый второй пациент с тяжелой неконтролируемой астмой имеет атопический фенотип, что составляет 5 от числа всех случаев БА каждый четвертый больной из данной группы имеет эозинофильной фенотип, что составляет 2,3 от числа всех случаев (n216). Заключение. Фенотипирование БА имеет важное прикладное значение для планирования эффективной таргетной терапии в популяции больных тяжелой неконтролируемой астмой.Topicality. Severe asthma is a heterogeneous and costeffective disease that requires a personalized treatment approach with inclusion of targeted therapy involving the phenotyping of asthma. Objective. Determine the dynamics of asthma prevalence in the Middle Ural, including severe asthma, and phenotype patients with severe asthma for the selection of targeted therapy. Materials and methods. Population studies of bronchial asthma prevalence were conducted in the Middle Ural from 2000 to 2012 using the standard ECRHS questionnaire. Also registers of patients with asthma were created. An analysis of outpatient records of patients with asthma was conducted in Ekaterinburg in 2018. The phenotyping of bronchial asthma was carried out by an allergistimmunologist. Results. The number of patients with bronchial asthma increased by 2.7 times over 17 years in the Middle Ural. Patients with mild asthma prevail in the population. The atopic asthma phenotype predominates in 70.881 of cases regardless of the population category. Severe uncontrolled bronchial asthma occurs in 10.2 of cases among all patients seeking medical care. Every second patient with severe uncontrolled asthma has an atopic phenotype, which is 5 of the total number of analyzed patients with bronchial asthma. Every fourth patient with severe uncontrolled bronchial asthma has an eosinophilic phenotype, which is 2.3 of all analyzed patients with bronchial asthma (n216). Conclusion. Phenotyping of asthma has important practical significance for planning effective targeted therapy in a population of patients with severe uncontrolled asthma.

scholarly journals Inhalation therapy for bronchial obstruction in children: traditional approaches and new opportunities

2021 ◽  
pp. 123-128
Author(s):  
Andrei V. Kamaev ◽  
Olga V. Trusova ◽  
Irina V. Makarova ◽  
Dmitrii S. Korostovtsev
Keyword(s):  
Bronchial Asthma ◽  
Respiratory Infections ◽  
Pediatric Population ◽  
Smooth Muscles ◽  
Practical Experience ◽  
Inhalation Therapy ◽  
Bronchial Obstruction ◽  
Acute Respiratory Infections ◽  
Chronic Infections ◽  
Asthma Attack

Acute respiratory infections are widespread in the pediatric population and represent a significant burden to the health care system and families of patients. Anatomic ans physiological features of preschool children and individual predisposition, especially atopic phenotype, determine high risk of complicated course of acute respiratory infections with bronchial obstruction syndrome. The etiological factors of recurrent AR are quite diverse from chronic infections to foreign bodies of the bronchi or genetically determined diseases, but the most common cause of recurrent AR in children remains bronchial asthma. Therapy of acute obstructive episode in real clinical practice is most often similar to therapy of bronchial asthma attack and includes effects on the main components of pathogenesis: contraction of smooth muscles, mucus hypersecretion and inflammatory edema of the bronchial wall. There has been accumulated a great practical experience of using combined preparation of fenoterol and ipratropium bromide, which currently exists also in the form of domestic medicinal product Astmasol-SOLOpharm. In addition to standard bronchodilator and mucoconstrictor therapy, hypertonic solutions, in particular Ingasalin 3%, are an important component of therapy of prolonged obstruction and relapse prevention. The possibilities of this remedy in shortening of terms of obstructive disorders and decrease of risk of antibiotic therapy are demonstrated by clinical example.

Sign in / Sign up

Export Citation Format

Share Document